3,549 Shares in Insulet Corporation $PODD Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC acquired a new position in Insulet Corporation (NASDAQ:PODD) during the second quarter, Holdings Channel.com reports. The firm acquired 3,549 shares of the medical instruments supplier’s stock, valued at approximately $540,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its stake in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet in the fourth quarter worth about $26,000. Elyxium Wealth LLC purchased a new position in Insulet in the fourth quarter valued at about $28,000. DV Equities LLC acquired a new stake in Insulet during the 4th quarter valued at approximately $28,000. Finally, MV Capital Management Inc. acquired a new stake in Insulet during the 4th quarter valued at approximately $29,000.

Insider Buying and Selling

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.36% of the stock is currently owned by insiders.

Analyst Ratings Changes

PODD has been the subject of several research analyst reports. Benchmark reduced their target price on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Stifel Nicolaus reduced their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. UBS Group dropped their target price on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price target on the stock. Finally, William Blair initiated coverage on Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating for the company. Fourteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $195.40.

Insulet Stock Up 1.2%

Shares of NASDAQ:PODD opened at $145.13 on Friday. The company’s fifty day moving average is $154.46 and its two-hundred day moving average is $181.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 27.13, a price-to-earnings-growth ratio of 1.14 and a beta of 1.10.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same period in the previous year, the business posted $1.17 EPS. The company’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
• Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.